Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. uri icon

authors

  • Wagemann, Olivia
  • Santacruz, Anna M
  • Andrew Aschenbrenner, PhD
  • Hassenstab, Jason J
  • Benzinger, Tammie L S
  • Gordon, Brian A
  • Coalier, Kelley A
  • Cruchaga, Carlos
  • Ibanez, Laura
  • Perrin, Richard J
  • Xiong, Chengjie
  • Liu, Haiyan
  • Li, Yan
  • Morris, John C
  • Lah, James J
  • Berman, Sarah B
  • Roberson, Erik D
  • van Dyck, Christopher H
  • Galasko, Douglas
  • Gauthier, Serge
  • Hsiung, Ging-Yuek R
  • Brooks, William S
  • Wang, Guoqiao
  • Pariente, Jérémie
  • Mummery, Catherine J
  • Day, Gregory S
  • Ringman, John M
  • Mendez, Patricio Chrem
  • St George-Hyslop, Peter
  • Fox, Nick C
  • Suzuki, Kazushi
  • Okhravi, Hamid R
  • Chhatwal, Jasmeer
  • Shi, Xinyu
  • Levin, Johannes
  • Jucker, Mathias
  • Sims, John R
  • Holdridge, Karen C
  • Proctor, Nicholas K
  • Yaari, Roy
  • Andersen, Scott W
  • Mancini, Michele
  • Llibre-Guerra, Jorge
  • Bateman, Randall J
  • Bittner, Tobias
  • McDade, Eric
  • Scelsi, Marzia A
  • Farlow, Martin R
  • Clifford, David B
  • Supnet-Bell, Charlene

publication date

  • June 1, 2024